Search

Your search keyword '"Adrien Besseiche"' showing total 5 results
Start Over Author "Adrien Besseiche" Publication Year Range Last 50 years
5 results on '"Adrien Besseiche"'

1. COVID-19 vaccine safety and effectiveness at 3 months in institutionalized old people

Author

Mathilde Malignac, Adrien Besseiche, Anaïs Cloppet-Fontaine, Mohand Ouali Sadeg, Jamileh Jafarbay, Mathilde Gourdon, Christophe Trivalle, Claude Jeandel, Jean-Sébastien Vidal, Olivier Hanon, and the COGEVAX study

Subjects
COVID-19, COVID-19 vaccine, Geriatric population, Nursing home, Institutionalization, Geriatrics, RC952-954.6
Abstract

Abstract Background Older age and associated comorbid conditions increase the risk of severe form of COVID-19 and death. The SARS-CoV-2 vaccination campaign began in France in December 2020 targeting institutionalized older population before having been evaluated in this population. The objective of our study was to assess the tolerability of vaccination 21 days (D21) and 90 days after the first vaccination (D90) in institutionalized old people. Secondary objective was to assess its effectiveness (mortality, hospitalization and occurrence of COVID) at D21 and D90. Methods People living in nursing homes or in long-term hospitalization facilities in France were included 12-2020-06-2021. They were divided into SARS-CoV-2 vaccinated and unvaccinated groups. Vaccine tolerability was prospectively assessed by the occurrence of health events at D21 and D90 (local and systemic side effects, geriatric syndromes, cardiovascular events). Vaccine efficacy was assessed by the occurrence of COVID-19 and serious adverse events (unscheduled hospitalization and all-cause mortality). Results The mean age of the 2595 participants was 86 years, 83% received COVID-19 vaccine. There were no significant difference between the vaccinated and unvaccinated for systemic or local adverse events at D21 and D90. At D90, vaccinated participants had significantly fewer SARS-CoV-2 infections (odds ratio (95% confidence interval) = 0.35 (0.22–0.58)), fewer deaths or hospitalizations (0.50 (0.31–0.81)), fewer cardiovascular events (0.28 (0.12–0.64)) and fewer pressure ulcers (0.38 (0.17–0.88)). Conclusions In this prospective cohort study, COVID-19 vaccine in a very old institutionalized geriatric population had a reassuring safety profile and a protective effect on COVID-19, hospitalizations and deaths, cardiovascular events and pressure ulcers.

Published
2024
Full Text
View/download PDF

2. Vers une meilleure acceptation des gérontechnologies

Author

Isabelle Dufour, Anaïs Cloppet-Fontaine, Anne-Bérénice Simzac, Melody Montheard, Clotilde Monnet, and Adrien Besseiche

Subjects
030506 rehabilitation, 03 medical and health sciences, 0302 clinical medicine, business.industry, Software deployment, Political science, General Medicine, Public relations, 0305 other medical science, business, 030217 neurology & neurosurgery
Abstract

Gerontotechnologies are becoming increasingly important for the elderly, their relatives and the professionals who accompany them. However, this deployment raises a large number of questions, fears and reluctance - or "technoscepticism" - including in the health and medico-social sectors. There are levers that could promote the successful implementation of these technologies.

Published
2021
Full Text
View/download PDF

3. [Towards a better acceptance of gerontotechnologies]

Author

Anaïs, Cloppet-Fontaine, Melody, Montheard, Adrien, Besseiche, Clotilde, Monnet, Anne-Bérénice, Simzac, and Isabelle, Dufour

Subjects
Technology, Humans, Aged
Abstract

Gerontotechnologies are becoming increasingly important for the elderly, their relatives and the professionals who accompany them. However, this deployment raises a large number of questions, fears and reluctance - or "technoscepticism" - including in the health and medico-social sectors. There are levers that could promote the successful implementation of these technologies.

Published
2021

4. Adaptive β-Cell Neogenesis in the Adult Mouse in Response to Glucocorticoid-Induced Insulin Resistance

Author

Ghislaine Guillemain, Marion Buyse, Emilie Courty, Thi Thu Huong Do, B. Blondeau, Fatima Mohamed Aguid, Bruno Fève, Evans Quilichini, Cécile Haumaitre, Pierre Gourdy, Jean-Pierre Riveline, Jean-François Gautier, Alexandrine Liboz, Melissa Buscato, Adrien Besseiche, Centre de Recherche Saint-Antoine (CRSA), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU), Unité de Recherche sur les Maladies Cardiovasculaires, du Métabolisme et de la Nutrition = Research Unit on Cardiovascular and Metabolic Diseases (ICAN), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Institut de Cardiométabolisme et Nutrition = Institute of Cardiometabolism and Nutrition [CHU Pitié Salpêtrière] (IHU ICAN), CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Centre de Recherche des Cordeliers (CRC (UMR_S_1138 / U1138)), École pratique des hautes études (EPHE), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Université Paris Diderot - Paris 7 (UPD7)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU), Institut de Biologie Paris Seine (IBPS), Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS), Institut des Maladies Métaboliques et Cardiovasculaires (I2MC), Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut National de la Santé et de la Recherche Médicale (INSERM), Institut de médecine moléculaire de Rangueil (I2MR), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées- Institut Fédératif de Recherche Bio-médicale Institution (IFR150)-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Hôpital Lariboisière, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Lariboisière-Fernand-Widal [APHP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Diderot - Paris 7 (UPD7), Université Sorbonne Paris Cité (USPC), Service de Pharmacie [CHU Saint Antoine], CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Barrières physiologiques et réponses thérapeutiques, Université Paris-Sud - Paris 11 (UP11), Service d'Endocrinologie, diabétologie et endocrinologie de la reproduction [CHU Saint-Antoine], Gestionnaire, Hal Sorbonne Université, Centre de Recherche Saint-Antoine (CR Saint-Antoine), Sorbonne Université (SU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Saint-Antoine [AP-HP], Unité de Recherche sur les Maladies Cardiovasculaires, du Métabolisme et de la Nutrition = Institute of cardiometabolism and nutrition (ICAN), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Pitié-Salpêtrière [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Sorbonne Université (SU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-IFR150-Institut National de la Santé et de la Recherche Médicale (INSERM), CHU Toulouse [Toulouse], Université Paris Diderot - Paris 7 (UPD7)-Hôpital Lariboisière-Fernand-Widal [APHP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Saint-Antoine [AP-HP], and Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Sorbonne Université (SU)

Subjects
Male, 0301 basic medicine, endocrine system, medicine.medical_specialty, Endocrinology, Diabetes and Metabolism, Cell, Nerve Tissue Proteins, 030209 endocrinology & metabolism, [SDV.BC]Life Sciences [q-bio]/Cellular Biology, Type 2 diabetes, Neogenesis, Mice, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, Insulin resistance, Corticosterone, Insulin-Secreting Cells, Internal medicine, Basic Helix-Loop-Helix Transcription Factors, Internal Medicine, medicine, Animals, Glucocorticoids, [SDV.BC] Life Sciences [q-bio]/Cellular Biology, [SDV.MHEP.EM] Life Sciences [q-bio]/Human health and pathology/Endocrinology and metabolism, geography, geography.geographical_feature_category, biology, Chemistry, SOX9 Transcription Factor, [SDV.MHEP.EM]Life Sciences [q-bio]/Human health and pathology/Endocrinology and metabolism, Flow Cytometry, Islet, biology.organism_classification, medicine.disease, In vitro, Mice, Inbred C57BL, Editorial Commentary, Diabetes Mellitus, Type 1, 030104 developmental biology, medicine.anatomical_structure, Endocrinology, Diabetes Mellitus, Type 2, Female, Insulin Resistance, Glucocorticoid, medicine.drug
Abstract

International audience; Both type 1 and type 2 diabetes are characterized by deficient insulin secretion and decreased β-cell mass. Thus, regenerative strategies to increase β-cell mass need to be developed. To characterize mechanisms of β-cell plasticity, we studied a model of severe insulin resistance in the adult mouse and defined how β-cells adapt. Chronic corticosterone (CORT) treatment was given to adult mice and led to rapid insulin resistance and adaptive increased insulin secretion. Adaptive and massive increase of β-cell mass was observed during treatment up to 8 weeks. β-Cell mass increase was partially reversible upon treatment cessation and reinduced upon subsequent treatment. β-Cell neogenesis was suggested by an increased number of islets, mainly close to ducts, and increased Sox9 and Ngn3 mRNA levels in islets, but lineage-tracing experiments revealed that neoformed β-cells did not derive from Sox9- or Ngn3-expressing cells. CORT treatment after β-cell depletion partially restored β-cells. Finally, β-cell neogenesis was shown to be indirectly stimulated by CORT because serum from CORT-treated mice increased β-cell differentiation in in vitro cultures of pancreatic buds. Altogether, the results present a novel model of β-cell neogenesis in the adult mouse and identify the presence of neogenic factors in the serum of CORT-treated mice.

Published
2018
Full Text
View/download PDF

5. Oxidative and energetic stresses mediate beta-cell dysfunction induced by PGC-1α

Author

Fabienne Foufelle, J.F. Gautier, L Delavallée, J-P Riveline, Adrien Besseiche, B. Blondeau, Centre de Recherche des Cordeliers (CRC), Université Pierre et Marie Curie - Paris 6 (UPMC)-École Pratique des Hautes Études (EPHE), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Université Paris Diderot - Paris 7 (UPD7)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM), Service de diabétologie et d'endocrinologie [CHU Lariboisière], Hôpital Lariboisière-Fernand-Widal [APHP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Université Pierre et Marie Curie - Paris 6 (UPMC)-École pratique des hautes études (EPHE), HAL-UPMC, Gestionnaire, Centre de Recherche des Cordeliers ( CRC ), Université Paris Diderot - Paris 7 ( UPD7 ) -École pratique des hautes études ( EPHE ) -Université Pierre et Marie Curie - Paris 6 ( UPMC ) -Université Paris Descartes - Paris 5 ( UPD5 ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ), and Hôpital Lariboisière

Subjects
0301 basic medicine, medicine.medical_specialty, Endocrinology, Diabetes and Metabolism, 030209 endocrinology & metabolism, Mice, Transgenic, Oxidative phosphorylation, Biology, medicine.disease_cause, 03 medical and health sciences, Mice, PGC-1, 0302 clinical medicine, Endocrinology, Oxygen Consumption, [ SDV.MHEP ] Life Sciences [q-bio]/Human health and pathology, Internal medicine, Insulin-Secreting Cells, Coactivator, Internal Medicine, medicine, Animals, Insulin, Beta (finance), Receptor, [SDV.MHEP.EM] Life Sciences [q-bio]/Human health and pathology/Endocrinology and metabolism, [SDV.MHEP] Life Sciences [q-bio]/Human health and pathology, Insulin secretion, Energetic stress, AMPK, General Medicine, [ SDV.MHEP.EM ] Life Sciences [q-bio]/Human health and pathology/Endocrinology and metabolism, [SDV.MHEP.EM]Life Sciences [q-bio]/Human health and pathology/Endocrinology and metabolism, Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha, Beta cell, 030104 developmental biology, Mitochondrial biogenesis, Oxidative stress, Glucocorticoid, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology, medicine.drug
Abstract

Aim Alteration of functional beta-cell mass in adults can be programmed by adverse events during fetal life. Previously, it was demonstrated that high glucocorticoid (GC) levels during fetal life participate in this programming by inhibition of beta-cell development. More specifically, GC levels stimulate expression of peroxisome proliferator-activated receptor-gamma coactivator 1-alpha (PGC-1α), a transcriptional co-regulator of the GC receptor (GR), which per se impairs beta-cell mass and function when overexpressed. As PGC-1α is also a potent inducer of mitochondrial biogenesis, our study aimed to determine how PGC-1α modifies mitochondrial function in beta cells and how it might regulate insulin secretion. Methods Beta-cell function was studied in mice overexpressing PGC-1α specifically in beta cells and in MIN6 cells overexpressing PGC-1α in vitro . Results PGC-1α overexpression in beta cells in vivo leads to a reduced beta-cell mass early in fetal life, whereas PGC-1α overexpression in vitro stimulates mitochondrial biogenesis and respiratory activity without improving ATP production, while increasing oxidative stress and impairing insulin secretion in response to glucose. While oxidative stress with PGC-1α overexpression in beta cells activates AMPK, it has also been revealed that blocking such oxidative stress or AMPK activation restores insulin secretion. Conclusion PGC-1α induces oxidative stress, which disrupts insulin secretion by AMPK activation. Thus, control of oxidative or energetic stress in beta cells may help to restore insulin secretion.

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results